258 results on '"Low, Eric"'
Search Results
52. Characterization of Patients with Rheumatoid Arthritis Treated with Rituximab or Tocilizumab in Post-Marketing Patient Registries: 878.
53. COMPARING DIAGNOSTIC METHODS TO MEASURE SPASTIC SEGMENT AND INFORM MYOTOMY LENGTH IN TYPE 3 ACHALASIA
54. Mo1316 ASSESSING PANESOPHAGEAL PRESSURIZATION IN SUPINE AND UPRIGHT POSITIONS IN TYPE II ACHALASIA
55. Mo1309 IDENTIFYING SPASTIC VARIANT OF TYPE II ACHALASIA AFTER TREATMENT WITH HIGH-RESOLUTION MANOMETRY AND FLIP PANOMETRY
56. Mo1301 ESOPHAGEAL CIRCULAR MUSCLE THICKNESS ON ENDOSCOPIC ULTRASOUND ACROSS DISORDERS OF ESOPHAGOGASTRIC JUNCTION OUTFLOW
57. Sa1118 CHARACTERIZING DISEASE BURDEN AND RISK FACTORS IN LARYNGOPHARYNGEAL REFLUX DISEASE
58. 854 ESTIMATED BURDEN OF SCREENING FOR BARRETT'S ESOPHAGUS IN THE UNITED STATES
59. Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study
60. Guidelines for the diagnosis and management of multiple myeloma 2011
61. Guidelines for supportive care in multiple myeloma 2011
62. Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
63. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
64. Survey of members of myeloma UK on biphosphonates-associated jaw osteonecrosis
65. NICE: friend and foe
66. Tailored myotomy for the treatment of type 3 achalasia: Is there a role for the functional lumen imaging probe?
67. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma
68. 982 – Risk Factors for Early-Onset Colorectal Cancer in a Sample of 68,067 US Veterans Undergoing Colonoscopy 1999-2014
69. Levofloxacin Prophylaxis in Newly Diagnosed Myeloma Patients
70. Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial.
71. Dietary management of eosinophilic esophagitis
72. Financing From the Perspective of Mining Companies
73. Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
74. Teochew Heritage Cooking
75. Patient Perception of Being Involved in a Clinical Trial for Multiple Myeloma Ceri Bygrave, Tanya Burton*, Patricia Carter, Sarah Richard, Eric Low, Charlotte Bloodworth
76. Complications and revision amputation following trauma-related lower limb loss
77. WHY PATIENTS SHOULD BE INVOLVED IN HEALTH TECHNOLOGY ASSESSMENT
78. A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial
79. Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial).
80. Accelerating target discovery using pre-competitive open science— patients need faster innovation more than anyone else
81. Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen
82. Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma.
83. Diagnostic Pathways of Myeloma Patients Presenting to Hospital Care and Relationship to End Organ Damage: An Analysis from the Teamm (Tackling EArly Morbidity and Mortality in Myeloma) Trial in 977 Patients
84. Enrichment of human embryonic stem cell derived motor neuron cultures using arabinofuranosyl cytidine
85. POTENTIAL FOR PATIENTS AND PATIENT-DRIVEN ORGANIZATIONS TO IMPROVE EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT
86. Improving Drilling-Operations Efficiency on an Ultranarrow-Margin High-Pressure/High-Temperature Managed-Pressure-Drilling Well With Use of a Mud Cap
87. Improving Drilling Operations Efficiency on an Ultra-Narrow Margin HPHT MPD Well with use of a Mud Cap
88. The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma
89. UK Patient Perspectives of Bisphosphonate Treatment Highlight a Lack of Knowledge On Therapeutic Benefits and Strong Preferences for Choice and Location of Treatment
90. Give a little to save a lot
91. Highly Advanced Multitechnical MPD Concept Extends Achievable HP/HT Targets in the North Sea
92. Many New Cancer Drugs in the United Kingdom Are Facing Negative NICE Rulings
93. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma
94. HPHT Well Control; An Integrated Approach
95. Gas Diffusion – Its Impact on a Horizontal HPHT Well
96. Improving Drilling-Operations Efficiency on an Ultranarrow-Margin High-Pressure/ High-Temperature Managed-Pressure- Drilling Well With Use of a Mud Cap.
97. Carbon-rich cyclopolymers: their synthesis, etch resistance, and application to 193-nm microlithography
98. guideline Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma.
99. Town and Gown: Tappan Square as a Paradigm of Oberlin's Changing Vision.
100. Carbon-rich cyclopolymers: Their synthesis, etch resistance, and application to 193 nm microlithography
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.